tradmap

USNA USANA HEALTH SCIENCES INC

$14.69 +2.69%

Data as of close

Healthcare · Medicinal Chemicals & Botanical Products

USANA HEALTH SCIENCES INC (USNA) is a healthcare company in the Medicinal Chemicals & Botanical Products industry, with a market capitalization of $271 million. Shares last traded at $14.69, 37.7% below their 52-week high. Over the past year the stock is down 25.5%. Net profit margin is -2.4%, above the peer median of -8.8%. Revenue grew 8.3% year over year.

Market Cap
$271M
Shares Out
18.5M
EPS (TTM)
-$1.18
P/E (TTM)*
—
P/S Ratio
0.30
P/B Ratio
0.52
Dividend / Share
—
Dividend Yield
—
52-Week High
$23.59
52-Week Low
$12.60
Volume (venue)
17,085
Avg Vol (3m, venue)
10,759.333

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

1W
+4.41%
1M
-0.88%
3M
-35.29%
6M
-20.81%
YTD
-25.09%
1Y
-25.54%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
50.78
SMA (50)
$14.58
SMA (200)
$18.08
Price vs SMA50
+0.78%
Price vs SMA200
-18.73%
ATR (14)
$0.53

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$913M
Net Income
-$22M
Gross Margin
77.4%
Operating Margin
-0.1%
Net Margin
-2.4%
Return on Equity
-4.2%
Return on Assets
-3.2%
Current Ratio
2.66
Debt / Equity
0.25
Revenue Growth (YoY)
+8.3%

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-07-04. Source: SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 -$1.16 2026-08-13
Q1 2026 $0.41 2026-05-12
Q4 2025 (derived) -$0.07 2026-03-16
FY 2025 $0.58 2026-03-16
Q3 2025 -$0.36 2025-11-05
Q2 2025 $0.52 2025-08-05

Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.

Full earnings history →

Medicinal Chemicals & Botanical Products peers

USNA vs 14 industry peers (Medicinal Chemicals & Botanical Products), by market cap. Data as of close

P/S vs peers
0.30 / 0.58 med
-49% discount
Net margin vs peers
-2.4% / -8.8% med
above median
1–14 of 14
DFTXDefinium Therapeutics, Inc.$4.4B———-10.70%
RGCRegencell Bioscience Holdings Ltd$3.1B———-5.00%
TRLVTrulieve Cannabis Corp.$2.1B—1.88-41.8%+8.19%
CRONCronos Group$1.2B17.646.8939.1%+1.52%
TLRYTilray Brands$375M—0.39-17.1%+0.40%
SNDLSNDL Inc.$337M———+2.81%
CGCCanopy Growth$288M—1.37-80.0%+4.07%
USNAUSANA HEALTH SCIENCES INC$271M—0.30-2.4%+2.69%
ACBAurora Cannabis$237M———+3.94%
GLASGlass House Brands Inc.$192M—1.05-16.3%+6.85%
NAGENiagen Bioscience, Inc.$190M11.881.4712.4%+2.56%
MDWDMediWound Ltd.$173M———+1.35%
FTLFFITLIFE BRANDS, INC.$78M12.450.776.2%+4.69%
BTMDbiote Corp.$33M5.560.183.2%+1.79%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.